Literature DB >> 20206885

Hepatocellular carcinoma: comparison of two different periods at the same center.

Maurizio Soresi1, Emanuele La Spada, Lydia Giannitrapani, Elisa Campagna, Valeria Di Gesaro, Walter Granà, Luigi Sandonato, Giuseppe Brancatelli, Giuseppe Rotolo, Andrea Affronti, Salvatore Messina, Giuseppe Montalto.   

Abstract

AIMS: To analyze the main etiological factors and some clinical characteristics of patients with HCC at diagnosis and to compare them with those we described ten years ago.
METHODS: 179 patients were included in Group 1, while 132 patients were included in Group 2. For all patients age, sex, serum markers of hepatitis B and C viruses, alcohol consumption, serum alpha feto-protein (AFP) levels and the main liver function parameters at HCC diagnosis were recorded.
RESULTS: Mean age was 66.0 years for Group 1 and 69.0 for Group 2 (P=0.005). HCV was responsible for 80.3% of HCC cases in Group 2 versus 72% in Group 1 (P=0.005). HBV alone and co-infection of HCV+HBV decreased, but not significantly. In Group 1 only four patients had an underlying normal liver, while in Group 2 no patients showed an underlying normal liver (P=ns). HCC was more frequently associated with Child class A in Group 2 (P=0.0001), whereas in Group 1 it was more frequently associated with class C (P=0.0001). Staging of HCC correlated inversely when patients of Groups 1 and 2 were compared (P<0.03). AFP serum levels were above normal in 72% of cases in Group 1 and in 41.5% in Group 2 (P=0.0001).
CONCLUSION: This study shows that over the last decade a number of characteristics of patients with HCC in our region have changed, particularly age at onset of HCC, staging of underlying liver disease and staging of HCC. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20206885     DOI: 10.1016/j.ejim.2009.12.011

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  6 in total

1.  Non invasive tools for the diagnosis of liver cirrhosis.

Authors:  Maurizio Soresi; Lydia Giannitrapani; Melchiorre Cervello; Anna Licata; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

2.  Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program?

Authors:  Florian Hucke; Wolfgang Sieghart; Maximilian Schöniger-Hekele; Markus Peck-Radosavljevic; Christian Müller
Journal:  Wien Klin Wochenschr       Date:  2011-07-29       Impact factor: 1.704

3.  Surveillance Program for Diagnosis of HCC in Liver Cirrhosis: Role of Ultrasound Echo Patterns.

Authors:  Maurizio Soresi; Antonino Terranova; Anna Licata; Antonietta Serruto; Giuseppe Montalto; Giuseppe Brancatelli; Lydia Giannitrapani
Journal:  Biomed Res Int       Date:  2017-05-30       Impact factor: 3.411

4.  The association of variants in PNPLA3 and GRP78 and the risk of developing hepatocellular carcinoma in an Italian population.

Authors:  Daniele Balasus; Michael Way; Caterina Fusilli; Tommaso Mazza; Marsha Y Morgan; Melchiorre Cervello; Lydia Giannitrapani; Maurizio Soresi; Rosalia Agliastro; Manlio Vinciguerra; Giuseppe Montalto
Journal:  Oncotarget       Date:  2016-12-27

5.  New landscapes and horizons in hepatocellular carcinoma therapy.

Authors:  Melchiorre Cervello; Maria R Emma; Giuseppa Augello; Antonella Cusimano; Lydia Giannitrapani; Maurizio Soresi; Shaw M Akula; Stephen L Abrams; Linda S Steelman; Alessandro Gulino; Beatrice Belmonte; Giuseppe Montalto; James A McCubrey
Journal:  Aging (Albany NY)       Date:  2020-02-04       Impact factor: 5.682

6.  The Changing Epidemiology of Hepatocellular Carcinoma :  Experience of a Single Center.

Authors:  Lydia Giannitrapani; Maddalena Zerbo; Simona Amodeo; Elisa Pipitone; Massimo Galia; Tancredi Vincenzo Li Cavoli; Maria Giovanna Minissale; Anna Licata; Cosima Schiavone; Giuseppe Brancatelli; Giuseppe Montalto; Maurizio Soresi
Journal:  Biomed Res Int       Date:  2020-02-27       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.